Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Oklahoma Medical Research FoundationFounded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Founded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Publication Number
US-11567077-B2
Publication Date
2023-01-31
Expiration Date
Abstract
The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.
Core Innovation
The invention discloses fully human monoclonal antibodies and panels comprising two or more serotype specific antibodies or binding fragments that bind Streptococcus pneumoniae or bind to antigens of S. pneumoniae immobilized on a solid support. Antibodies are defined by heavy and light chain variable domain sequences (SEQ ID NOS: 258 to 268, 287 to 293, 305, 325 to 330, 355 to 359; and 270 to 285, 306 to 312, 324, 338 to 343, 369 to 373). Panels target capsular and cell-wall polysaccharide (CWPS) antigens. Panel embodiments bind multiple serotypes, including panels that bind at least 15 serotypes and panels that bind 18 or more serotypes.
Panel embodiments specify immobilization on solid supports such as beads, dipstick, filter, membrane, plate, chip, or column matrix. Antibodies are provided in formats including IgG, Fab, scFv, and single-domain and may be conjugated to detectable labels, antibiotics, nanoparticles, or liposomes for diagnostic or therapeutic applications. Panels and kits are defined by sequence and antigen specificity and target Streptococcus pneumoniae capsular and cell-wall polysaccharide (CWPS) antigens.
The partial content reports nucleotide sequences and variable region characterization of human monoclonal antibodies [procedural detail omitted for safety]. It reports serotype specificities including named serotypes and CWPS, rates of cross-reactivity and poly-reactivity, high somatic hypermutation indicative of an anamnestic memory response, donor-specific serotype coverage fingerprints, and clonality observations. It describes potential passive immunotherapeutic application of fully human monoclonal antibodies; the problem being solved is not explicitly described in patent.
Claims Coverage
Overview of claim coverage. Four inventive features are identified across two independent claims.
Panel of serotype specific antibodies immobilized on a solid support
A panel comprising two or more serotype specific antibodies or binding fragments that bind to Streptococcus pneumoniae or bind to antigens of S. pneumoniae immobilized on a solid support.
Antibodies defined by heavy and light chain variable domain sequences
The antibodies comprise a heavy chain variable domain polypeptide selected from SEQ ID NOS: 258 to 268, 287 to 293, 305, 325 to 330, and 355 to 359 and a light chain variable domain polypeptide selected from SEQ ID NOS: 270 to 285, 306 to 312, 324, 338 to 343, and 369 to 373.
Kit comprising panel, container, and immunodetection reagent
A kit for the detection of Streptococcus pneumoniae comprising a panel of one or more serotype specific antibodies or binding fragments, a suitable container, and an immunodetection reagent.
Panel selected to bind listed S. pneumoniae serotypes and CWPS
The panel is selected to bind S. pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 11B, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F, and CWPS.
The independent claims cover (1) a panel of two or more serotype specific antibodies or binding fragments that bind S. pneumoniae or its antigens immobilized on a solid support and that are defined by specified heavy and light chain variable domain sequences, and (2) a detection kit comprising the antibody panel together with a suitable container and an immunodetection reagent, wherein the panel is selected to bind an enumerated set of S. pneumoniae serotypes and CWPS.
Stated Advantages
Not explicitly described in patent.
Documented Applications
A kit for detection comprising the antibody panel immobilized on a solid support, a suitable container, and an immunodetection reagent.
Diagnostic detection of Streptococcus pneumoniae in subject samples [procedural detail omitted for safety] using the antibody panel.
Immunodetection methods using the antibody panel [procedural detail omitted for safety].
Therapeutic use of the antibodies alone or in combination with antibiotics such as vancomycin and levofloxacin for treatment.
Potential passive immunotherapeutic application of fully human monoclonal antibodies.
Interested in licensing this patent?